A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression
Indexed incrossrefpubmed
Abstract
Objectives
To determine whether inhibition of the inflammatory cytokine tumor necrosis factor (TNF) reduces depressive symptoms in patients with treatment-resistant depression and whether an increase in baseline plasma inflammatory biomarkers, including high-sensitivity C-reactive protein (hs-CRP), TNF, and its soluble receptors, predicts treatment response.
Design
Double-blind, placebo-controlled, randomized clinical trial.
Citation impact
1,570
total citations
- FWCI
- 23.33
- Percentile
- 100%
- References
- 71
Citations per year
Authors
8Topics & keywords
Topics
Keywords
- Medicine
- Placebo
- Internal medicine
- Infliximab
- Randomized controlled trial
- Depression (economics)
- Tumor necrosis factor alpha
- Antidepressant
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.